does not seem to be decreasing despite the continuing sensitivity to penicillin of the causative agents and the recent advent of efficacious vaccines.4
Methods
All data given are based on records kept at a central national laboratory in each country. Collection of the data was helped because for decades statutory nominal reports on the disease have been sent to the central office by the hospital wards or the isolating laboratory, or both.
The reliability of the reports was tested in Finland in 1976-80,8 and results showed at least 900/ coverage of the actual cases in the country. A very effective surveillance was also the rule in the other Scandinavian countries because the epidemics in the 1970s had caused much concern about the problem.
In Norway and Sweden the centre has regularly published an epidemiological synopsis giving data also on meningococcal disease; in other cases such information has been published only incidentally in scientific or epidemiological reports.'-3 "-1 Serogrouping and antimicrobial sensitivity determinations of isolated meningococci were in most cases performed or confirmed in the respective national laboratories. Several 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 Occurrence of meningococcal disease in Scandinavia to end of 1970s. Presumable or proved serogroups causing major epidemics marked with capitals. m -Million.
The yearly incidence rate of meningococcal disease has been generally around 3 0-5 0/100 000. Table I gives the incidences of the past 10 years; the figures for northern Norway are given separately because of the peculiar distribution of the disease there (see below).
The highest incidence of 37-7/100 000 was reached in Iceland in 1976 and the morbidity has remained rather high since then, but because of the small population of the country (226 000 inhabitants) the total number of cases has been modest. The lowest yearly incidences were seen in 1972 and 1979 in Sweden (1 1 and 1-2/100 000), where the disease has remained rare, and in 1979 after the epidemic in Finland (1 2/100 000).
Seasonal variation has been small with some exceptions, such as the extremely high incidence in March 1978 in Norway. '8 but none were serogrouped. The peak incidence was reached in 1976 with 83 cases (37 7/100 000). During the first six months of that year, meningococci were cultured from 19 of 40 cases; of these 19, eight were of group A, three of group B, and eight strains could not be serogrouped. From August 1976 to the end of 1979, specimens were available from 134 out of a total of 145 meningococcal cases. Of 109 strains grown, 94 were of serogroup B, and one of group C (in July 1979); 14 were ungroupable.
A rather different occurrence has been seen in Norway.2 10 After 15 years, obviously with a slight preponderance of group A, there was in 1974 a sharp increase in the number of patients with group B meningococci.14 The numbers have remained high since then. The incidence reached its peak in northern Norway in 1975-23-9/100 000 (table I). The epidemic has been restricted (now for more than seven years) to the three most northern counties, Nordland, Troms, and Finnmark, an area with roughly 600 000 inhabitants, and only a slow movement to the south has been observed. In the rest of the country the total incidence has been one-third of that in northern Norway, around 5 to 6/100 000/year. During 1975-9, 1214 isolates (from 1574 cases) were serogrouped. Of these, 815 (67%) belonged to group B. In 1979 group B was responsible for 84% of all the clinical isolates in Norway. 10 Of the other serogroups, group C has been more common (roughly 10-15"( more) than A. Other serogroups have been found only occasionally (at most, two group Y cases in both 1975 and 1978). In addition one group X case was diagnosed in 1975 and one group Z in 1978. In general, the resistance of meningococci increased only in the beginning of the decade. In northern Norway2 a fast shift in all meningococcal groups to sulphonamide-resistant forms occurred in 1972 (920' of the 84 strains tested in 1974-5 showed MIC values of sulfadiazine equal to or more than 50 ,ug/ml), whereas in Finland only the epidemic group A (practically all strains of it) was resistant. 30 In Iceland only five strains from the years 1975-8 were interpreted (by the disc diffusion method) as fully resistant (100 ,ug/ml). In 1979, however, more than half of group B and one group C strains were resistant.
In Sweden the resistance of all groups increased in the early part of the 1970s so that in 1972 620o of the strains tested were resistant (but the MIC break-off point was 16 Htg/ml, which is lower than that used in the other countries). Three years later this percentage was found somewhat decreased to 52." In Denmark only sporadic strains have shown increased resistance to sulphonamides. They have belonged mostly to groups B and C, and only to a lesser extent to A.
AGE AND SEX DISTRIBUTION
The age distribution of the cases has in each country been roughly the same and similar to that typical of industrialised countries, which is different from that, for example, in the meningitis belt of Africa.23 Thus children under 5 years were most prone to the disease. In the epidemic conditions in Iceland 78",,, and in northern Norway 33o^, of the patients belonged to this age group. On the other hand, during the epidemic in Finland there was a pronounced shift towards older age groups,' but this change returned to "normal" soon after the epoidemic.
The second most vulnerable five years' age group was that among 15-19 years.' "0 In northern Norway, for example, the average annual incidence was 22-6/100 000, which did not solely reflect the high morbidity among the recruits in the defence forces"9 32 because the same higher incidence was seen among women. From the age of 25 on the incidence has remained low (around 2/100 000/year in Finland).
On the whole, roughly 75-800' of the patients have been under 25.
In general men have been the majority. In some instances this was due to special social conditions: the reported excess of men (42 Male excess was seen in all age groups in Norway in 1975-9:
among the 1558 patients the annual incidence'0 was 8 11100 000, which is slightly higher than in women (7 3/100 000). In non-epidemic countries the morbidity of the two sexes has been rather similar.
CA'E FATALITY RATES
The overall case death rate has varied considerably, from about 5 to 15°" (table III) . The present high figures of Norway are worse than earlier: among 124 patients in the Oslo area during 1966-76 the overall death rate was 8 90'.' The rate in northern Norway has been con-BRITISH MEDICAL JOURNAL VOLUME 284 29 MAY 1982 nected with the higher proportion of meningococcaemia without meningitis in this epidemic."0 In the series of 1246 cases collected in 1975-8 the overall case death rate was as high as 12 6)10. ' Among the 370 patients (during the epidemic) in the Helsinki area, Finland,21 the death rate of meningitis was 2-7,T, but of septicaemia without meningitis much higher, 9 2",. This finding coincides with the general experience on meningococcal disease.9 13 23 The sex of the patient had a clear influence on the outcome of the disease. This was best seen in northern Norway in 1975-7, when the overall case death rate was 20°) among 101 men but only 71"0 among 83 women2 (p <005). The same trend was described in southern Norway in the years 1966-7613: seven (11",) out of 64 men and four (7 " X) of 60 women died from meningococcal disease. Regarding the 22 fatal cases of the (214) patients in Iceland (1975-9) , there were 16 men (14")) against six (6),') women (difference not significant).
Discussion
The problem of meningococcal disease has not passed. 33 The five Scandinavian countries alone have experienced three epidemics in 10 years. The total number of cases during the epidemics in Finland, Iceland, and Norway exceeded 3300. Over 300 people have died despite the fact that the problem has been recognised, medical facilities have been readily available even in the remote northern areas, and treatment has been started promptly. With the non-epidemic incidence of meningococcal disease of 3/100 000/year or under (table I, figure) and case fatality rate of 51/ 13 The epidemic strain in both the latter epidemics, however, was of serotype 2 whereas that in Norway is of type 15.14 The lack of an effective vaccination against the group B meningococci4I has necessitated evaluation of chemoprophylaxis. Sulphonamide sensitivity of the epidemic strain allowed effective mass prophylaxis with this drug in Alabama,40 but the epidemic strain in Norway is highly resistant. The only other drugs that have been shown to be able to affect the carrier are rifampicin or minocycline,42 which, however, are not suitable for mass prophylaxis. An effective vaccine, perhaps the experimental outer membrane protein vaccines,44 would be essential. An additional problem, however, is that the Norwegian epidemic is not caused by the serotype 2 from which the protein vaccines have so far been prepared. Attempts to improve the immunogenicity of the group B capsular polysaccharide by increasing its molecular weight have so far not produced positive results. 41 Currently a meningococcal epidemic is continuing in one Scandinavian country (Norway), and not much can be done to stop it; fortunately, its highest peak seems to be over ( figure,  table I ). On the other hand, the high (12 80) case fatality rate also in southern Norway is alarming because this part of the country has so far not belonged to the epidemic area. There is a fear that high mortality predicts an epidemic as was the case in Zaria, Nigeria: the gravest toll was paid in the beginning of the outbreak, whereafter the virulence of the (group A) epidemic strain seemed to decrease.23 Whether this finding applies generally remains to be seen. A detailed surveillance is thus of paramount importance to find every major change in the epidemiological equilibrium. It requires very good international co-operation in the future.
